MBP 7595

Drug Profile

MBP 7595

Latest Information Update: 28 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Briana Bio-Tech; Nonindustrial source
  • Class Neuroprotectants; Peptides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 12 Jan 2001 No-Development-Reported for Multiple sclerosis in Canada (IV)
  • 09 Jul 1998 Phase-II clinical trials for Multiple sclerosis in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top